21 results about "Receptor type" patented technology

Compositions and methods for editing, e.g., altering, DNA sequences within TGFβR2 are provided. Compositions and methods for reducing or eliminating TGFβR2 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.

Provided in the present invention are an siRNA for inhibiting the expression of the activin A receptor type 1C (ACVR1C) gene, and a conjugate thereof. The siRNA comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 consecutive nucleotides that differ from nucleotide sequences set forth in SEQ ID NO: 1236-SEQ ID NO: 2470 by no more than 4 nucleotides. The antisense strand is 17-30 nucleotides in length; and the sense strand is 17-30 nucleotides in length, and is at least partially or completely complementary to the antisense strand. The siRNA, siRNA conjugate and pharmaceutical composition provided in the present invention exhibit good stability, great ACVR1C gene inhibitory activity, and satisfactory cytotoxicity and immunostimulatory activity.

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3 / 14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

The present disclosure provides methods and compositions for reducing the addictive liability of opioid analgesics in a subject, for example, by co-administering to the subject the opioid and a serotonin receptor type 2 (5HT2) agonist or a serotonin (5HT) releasing agent. The disclosed methods include methods for preventing opioid abuse, methods for reducing the rewarding effect of an opioid, methods for reducing the addictive liability of an opioid, methods for eliminating or substantially reducing the tendency for a subject to develop physical dependence, tolerance, and / or withdrawal symptoms with respect to an opioid, and methods for eliminating or substantially reducing the tendency for a subject to use opioids in ways not prescribed, take opioids more often or in larger amounts than prescribed, and / or use opioids recreationally. The methods can be performed on a subject, such as a patient (e.g., a human patient).

Provided herein are useful for degrading protein tyrosine phosphatase, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and useful for treating related diseases, disorders and conditions that contribute to the treatment of PTPN1 or PTPN2 degrading agents, degradation agent compounds, compositions, and methods for treating cancer, such as cancer or metabolic diseases.

Provided herein are methods of using a combination comprising protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1) and an additional therapeutic agent to treat a disease (e.g., cancer or metabolic disease) that produces an advantageous response to PTPN1 or PTPN2 inhibitor treatment.

The present application relates generally to the field of bone morphogenetic protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for treating degenerative and / or demyelinating diseases of the nervous system.

The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and / or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.

The present invention addresses the problem of providing a method for simply and efficiently inducing oocytes and prespermatogonium cells to differentiate from primordial germ cell-like cells or primordial germ cells. This problem is solved by a method for producing oogonium cells or prespermatogonium cells, which comprises a step for culturing primordial germ cell-like cells or primordial germ cells in a culture medium containing a BMP receptor type 2 signaling agonist to obtain oogonium cells or prespermatogonium cells.

A population of genetically engineered T cells, comprising a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene and optionally a disrupted TRAC gene, a disrupted β2M gene, and / or a disrupted CD70 gene. Also provided herein are methods for making such genetically engineered T cells and therapeutic uses thereof.

The invention discloses an alkaline phosphatase response type near-infrared fluorescent probe and a preparation method and application thereof, the fluorescent probe is a compound XDM-P, the molecular structure of the fluorescent probe comprises a donor-pi-conjugate-receptor type near-infrared fluorophore constructed by taking xanthene and cyanoisophorone as parent nucleuses, and a recognition group linked by a phosphate bond; the preparation method comprises Knoevenagel condensation, phosphorylation and selective dealkylation reaction. The probe is subjected to specific hydrolysis under the action of alkaline phosphatase (ALP), the intramolecular charge transfer effect is recovered, and near-infrared fluorescence 'OFF-ON' response at 774 nm is realized. The probe provided by the invention has high sensitivity, good linear response and deep tissue penetrating ability, and can be used for intracellular ALP detection and non-invasive, real-time and semi-quantitative in-vivo fluorescence imaging of liver cancer tumor-bearing mouse and drug-induced liver injury mouse models.

The present invention relates to new compounds of formula (1):as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR1B), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.

The present disclosure relates to CRISPR-related systems and components for targeting, editing, and / or modulating expression of a PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) gene. The present disclosure also relates to methods and applications thereof in connection with engineered immunocompetent cells including T cells or T cell precursors.

The invention relates to a novel epitope of PTPRZ1 which presents good immunogenicity and is useful for immunotherapy of cancer.

The present disclosure provides a culture medium for cell culturing, the culture medium containing a combination of specific components. The present disclosure provides a culture medium which contains a combination of components selected from the group consisting of: (1) a halcinonide component; (2) an ALK4 / 7 inhibitor or a TGFβ receptor type-1 kinase inhibitor; (3) a BRD7 / 9 double degradation factor or a BRD7 / 9 binding molecule (degradation factor); (4) an LATS1 / 2 inhibitor, a PKA inhibitor, or an AKT1 inhibitor; (5) a CK1 / 2 inhibitor, an insulin receptor inhibitor, a Tyr kinase inhibitor, a PKA inhibitor or a PKC inhibitor, or an adenosine kinase inhibitor; (6) an E-selectin inhibitor, a VCAM1 inhibitor, or an ICAM1 inhibitor; and (7) an LATS1 inhibitor + an LATS2 inhibitor.

Device (1) for determining a combined anesthetic effect on a patient anesthetized by means of a combination of at least two active substances characterized in that the device is set up to perform the following steps: Determining the concentration of each active ingredient at the site of action using pharmacokinetic and / or pharmacodynamic models; Summarizing the effect of all active ingredients within each class of active ingredients used, whereby the potency of the active ingredients is added if they act on the same receptor type; Determining the synergistic interaction between at least two active substances used in anesthesia by determining a combined potency N of the anesthetic effect of the applied active substances, based on a mean anesthetic efficacy of the active substances used and an interaction term. determining an NSRI index value NSRI = 100 ∗ ( 1 − ( N / N ' ) sl 1 + ( N / N ' ) sl ) , where - N is the combined power, - N' is a specific value at which an NSRI value of 50% is reached. - and sl is a slope factor for a transformation from N to NSRI; Display of the NSRI index value using a display device (29); and Display of at least one comparative value (67, 69) for anesthesia management and / or patient arousal by means of the display device (29).

This specification provides a method for using compounds that bind to interleukin-1 beta (IL-1β) in the interleukin-1 beta (IL-1β) binding pocket identified herein, thereby capturing IL-1β and inhibiting its interaction with the interleukin-1 receptor type I (IL-1R1).

The present invention relates to new compounds of formula (I):as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR1B), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.

The invention relates to the technical field of environmental protection, and provides a synthesis method and application of a central receptor type covalent organic framework. According to the method, 2, 4, 6-trihydroxy-1, 3, 5-benzenetricarboxaldehyde, McLeod acid and 2, 6-naphthylenediamine are taken as monomers, and a Mannich type polycondensation strategy is adopted, so that the central receptor type covalent organic framework Tp-ND-H is synthesized under the catalysis of benzotriazole-1-yl-oxytripyrrolidinyl phosphorus hexafluorophosphate. The Tp-ND-H has the advantages of being adjustable in energy level, high in exciton migration efficiency, good in structural stability and the like, is high in U (VI) photocatalytic reduction capacity, high in efficiency and good in selectivity, and has a good application prospect.